Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6912100 | 0.98 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL258275 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL22230793 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL10608661 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL258318 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL625931 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL21439847 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL21437266 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL20483847 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL21440331 | 0.81 | CYP3A4 (0.80) | CYP3A4LPAR3LPAR2LPAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470829-B2 | Imidazolidine derivative and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-1790640-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-7018993-B2 | Antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-0798298-B1 | THIAZOLIDINONE OR OXAZOLIDINONE DERIVATIVES TO TREAT ANGINA PECTORIS OR COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO CO (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-0812835-B1 | OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES | SANKYO CO (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5925658-A | PREVENTING OR TREATING ANGINA PECTORIS | SANKYO COMPANY, LIMITED (JP) | 1999-07-20 | — | — | US | disclosed |
| US-5891898-A | ANTIULCER AGENT | SANKYO COMPANY, LIMITED (JP) | 1999-04-06 | — | — | US | disclosed |
| US-5843973-A | Thiazolidinone compounds and composition for angina pectoris comprising the compounds as an active ingredient | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0812835-A1 | OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1997-12-17 | — | — | EP | disclosed |
| EP-0798298-A1 | THIAZOLIDINONE COMPOUNDS OR ANGINA PECTORIS REMEDY OR PREVENTIVE CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO COMPANY LIMITED (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CBR1, NR0B1, CNKSR1 | CYP3A4 969/4885LPAR3 2529/4885LPAR2 3586/4885 |
| US-20030158164-A1 | Novel antiandrogenic agent | NR5A1, CYP19A1, HSD17B11 | CYP3A4 728/4885LPAR3 3200/4885LPAR2 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.